Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX000189 in Chemotherapy-Induced Peripheral Neuropathy
NCT07601386Phase 1Not yet recruiting
- Sponsor
- Jeyou Pharmaceutical
- Start
- May 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of JMKX000189 in chemotherapy-induced peripheral neuropathy (CIPN) (3 arms), sponsored by Jeyou Pharmaceutical. Primary endpoint: Incidence and severity of adverse events and serious adverse events at 6 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
JMKX000189
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07601386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601386.